SG11201803816RA - Targeting of the formyl-peptide receptor 2/lipoxin a4 receptor (fpr2/alx) for treatment of heart disease - Google Patents

Abstract

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property -' Organization International Bureau (43) International Publication Date ..... ...sr ,„,„1 1 June 2017 (01.06.2017) WIPO I PCT ID Hit (10) WO International 2017/091496 1111111111111111111111111111111111111111111111111111111111111t111111111111111 Publication Number Al (51) International Patent Classification: AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, A61K 31/00 (2006.01) A61P 9/00 (2006.01) BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, A61K 31/4152 (2006.01) A61P 9/10 (2006.01) DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR, (21) International Application Number: KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, PCT/US2016/063036 MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, (22) International Filing Date: OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, 21 November 2016 (21.11.2016) SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, (25) Filing Language: English ZW. (26) Publication Language: English (84) Designated States (unless otherwise indicated, for every (30) Priority Data: kind of regional protection available): ARIPO (BW, GH, 62/259,498 24 November 2015 (24.11.2015) US GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, (71) Applicant: BRISTOL-MYERS SQUIBB COMPANY TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, [US/US]; Route 206 and Province Line Road, Princeton, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, New Jersey 08543 (US). LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, (72) Inventors: OSTROWSKI, Jacek; c/o Bristol-Myers GW, KM, ML, MR, NE, SN, TD, TG). Squibb Company, 311 Pennington-Rocky Hill Road, Pen- nington, New Jersey 08534 (US). GARCIA, Ricardo; c/o Declarations under Rule 4.17: Bristol-Myers Squibb Company, 311 Pennington-Rocky as to applicant's entitlement to apply for and be granted a Hill Road, Pennington, New Jersey 08534 (US). WURTZ, patent (Rule 4.170) c/o - Nicholas R.; Bristol-Myers Squibb Company, 311 Pen nington-Rocky Hill Road, Pennington, New Jersey 08534 — as to the applicant's entitlement to claim the priority of the (U S) earlier application (Rule 4.17(iii)) . (74) Agents: EPPERSON, James al.; Bristol-Myers Squibb — of inventorship (Rule 4.17(iv)) et Company, Route 206 and Province Line Road, Princeton, Published: New Jersey 08543 (US). — with international search report (Art 21(3)) (81) Designated States (unless otherwise indicated, for every kind AE, AG, AL, AM, of national protection available): 1-1 .4t 0\ il• 1-1 0\ 0 It -- - 1-1 C:= (54) Title: TARGETING OF THE FORMYL-PEPTIDE RECEPTOR 2/LIPDXIN A4 RECEPTOR (FPR2/ALX) FOR TREAT- \" MENT OF HEART DISEASE C ) „,.. (57) : The disclosure generally relates to a therapeutic approach based on the stimulation of resolution of inflammation by the Foiinyl-Peptide Receptor 2/Lipoxin A4 receptor (FPR2/ALX) for the treatment of heart disease.